FDA creates new category for ultrasound pain management device
The US Food and Drug Administration created a new category for ZetrOZ's Acoustic Medicine device
ZetrOZ, a medical technology company that produces wearable ultrasound devices to reduce pain and inflammation, now comes under a new FDA category, created for just these types of therapeuties.
ZetrOZ's sustained acoustic medicine device is an at-home, long-duration ultrasound therapy instrument, where patients, such as teenage and adult athletes recovering from sports injuries get trained on the use of the device, and then can apply it directly at home. The device can treat inflammation, pain, and other unresolved medical issues such as cartilage degeneration, miniscus injuries and ankle sprains. The localized treatment allows healing without a surgical procedure, and is typically applied once a day for 6 to 8 weeks.
The FDA initially cleared ZetrOZ's sustained acoustic medicine device in 2013, with expanded indications in 2020.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
